Compass Historical Income Statement

CMPX Stock

USD 1.49 0.11 7.97%

Historical analysis of Compass Therapeutics income statement accounts such as Net Interest Income of 8.3 M, Interest Income of 8.3 M or Depreciation And Amortization of 1.7 M can show how well Compass Therapeutics performed in making a profits. Evaluating Compass Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Compass Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Compass Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Compass Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compass Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

About Compass Income Statement Analysis

Compass Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Compass Therapeutics shareholders. The income statement also shows Compass investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Compass Therapeutics Income Statement Chart

At this time, Compass Therapeutics' Tax Provision is fairly stable compared to the past year. Net Interest Income is likely to rise to about 8.3 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.7 M in 2024.

Interest Income Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Interest Income

Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Compass Therapeutics. It is also known as Compass Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Compass Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Compass Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compass Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.At this time, Compass Therapeutics' Tax Provision is fairly stable compared to the past year. Net Interest Income is likely to rise to about 8.3 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.7 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.6M	1.9M	1.9M	1.7M
Interest Income	29K	2.4M	7.9M	8.3M

Depreciation And Amortization Interest Income

Compass Therapeutics income statement Correlations

	Tax Provision	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue	Non Operating Income Net Other	Non Recurring	Selling And Marketing Expenses
Tax Provision		-0.68	-0.64	0.2	-0.73	-0.64	-0.18	0.52	0.39	0.34	-0.08	0.34	-0.14	0.24	0.39	-0.62	0.36	0.78	-0.54	0.64	-0.84	-0.57	0.56
Net Interest Income	-0.68		1.0	-0.32	0.92	0.64	0.7	-0.31	-0.07	-0.91	0.6	-0.9	0.67	-0.46	-0.08	0.99	-0.07	-0.87	0.38	-0.64	0.92	0.92	-0.92
Interest Income	-0.64	1.0		-0.27	0.92	0.65	0.7	-0.26	-0.03	-0.91	0.6	-0.9	0.66	-0.43	-0.03	0.99	-0.02	-0.84	0.33	-0.61	0.9	0.93	-0.93
Depreciation And Amortization	0.2	-0.32	-0.27		-0.09	0.2	-0.38	0.57	0.51	0.42	-0.42	0.46	-0.4	0.78	0.51	-0.38	0.5	0.22	-0.53	0.57	-0.3	-0.21	0.29
Interest Expense	-0.73	0.92	0.92	-0.09		0.69	0.64	-0.11	0.11	-0.79	0.54	-0.78	0.62	-0.25	0.11	0.9	0.13	-0.97	0.28	-0.52	0.96	0.79	-0.8
Selling General Administrative	-0.64	0.64	0.65	0.2	0.69		0.05	0.11	0.26	-0.37	-0.09	-0.35	0.01	0.22	0.26	0.56	0.26	-0.59	-0.21	-0.12	0.6	0.57	-0.7
Other Operating Expenses	-0.18	0.7	0.7	-0.38	0.64	0.05		-0.04	0.15	-0.85	0.99	-0.86	1.0	-0.4	0.15	0.76	0.16	-0.66	0.3	-0.32	0.64	0.7	-0.47
Operating Income	0.52	-0.31	-0.26	0.57	-0.11	0.11	-0.04		0.97	0.17	-0.04	0.19	-0.02	0.75	0.97	-0.32	0.97	0.17	-0.91	0.86	-0.34	-0.28	0.3
Net Income From Continuing Ops	0.39	-0.07	-0.03	0.51	0.11	0.26	0.15	0.97		-0.06	0.12	-0.03	0.16	0.66	1.0	-0.08	1.0	-0.04	-0.86	0.73	-0.13	-0.07	0.09
Ebit	0.34	-0.91	-0.91	0.42	-0.79	-0.37	-0.85	0.17	-0.06		-0.8	1.0	-0.85	0.57	-0.05	-0.94	-0.06	0.74	-0.3	0.56	-0.78	-0.81	0.84
Research Development	-0.08	0.6	0.6	-0.42	0.54	-0.09	0.99	-0.04	0.12	-0.8		-0.81	0.99	-0.44	0.12	0.67	0.13	-0.58	0.33	-0.3	0.55	0.61	-0.37
Ebitda	0.34	-0.9	-0.9	0.46	-0.78	-0.35	-0.86	0.19	-0.03	1.0	-0.81		-0.85	0.59	-0.03	-0.94	-0.04	0.73	-0.32	0.57	-0.77	-0.8	0.84
Total Operating Expenses	-0.14	0.67	0.66	-0.4	0.62	0.01	1.0	-0.02	0.16	-0.85	0.99	-0.85		-0.42	0.16	0.73	0.18	-0.65	0.29	-0.32	0.61	0.66	-0.44
Reconciled Depreciation	0.24	-0.46	-0.43	0.78	-0.25	0.22	-0.4	0.75	0.66	0.57	-0.44	0.59	-0.42		0.66	-0.52	0.66	0.29	-0.78	0.88	-0.42	-0.29	0.49
Income Before Tax	0.39	-0.08	-0.03	0.51	0.11	0.26	0.15	0.97	1.0	-0.05	0.12	-0.03	0.16	0.66		-0.08	1.0	-0.03	-0.86	0.74	-0.13	-0.07	0.09
Total Other Income Expense Net	-0.62	0.99	0.99	-0.38	0.9	0.56	0.76	-0.32	-0.08	-0.94	0.67	-0.94	0.73	-0.52	-0.08		-0.07	-0.85	0.41	-0.66	0.91	0.91	-0.91
Net Income	0.36	-0.07	-0.02	0.5	0.13	0.26	0.16	0.97	1.0	-0.06	0.13	-0.04	0.18	0.66	1.0	-0.07		-0.07	-0.84	0.72	-0.1	-0.07	0.09
Income Tax Expense	0.78	-0.87	-0.84	0.22	-0.97	-0.59	-0.66	0.17	-0.04	0.74	-0.58	0.73	-0.65	0.29	-0.03	-0.85	-0.07		-0.37	0.54	-0.98	-0.71	0.69
Gross Profit	-0.54	0.38	0.33	-0.53	0.28	-0.21	0.3	-0.91	-0.86	-0.3	0.33	-0.32	0.29	-0.78	-0.86	0.41	-0.84	-0.37		-0.88	0.49	0.33	-0.26
Cost Of Revenue	0.64	-0.64	-0.61	0.57	-0.52	-0.12	-0.32	0.86	0.73	0.56	-0.3	0.57	-0.32	0.88	0.74	-0.66	0.72	0.54	-0.88		-0.67	-0.48	0.64
Non Operating Income Net Other	-0.84	0.92	0.9	-0.3	0.96	0.6	0.64	-0.34	-0.13	-0.78	0.55	-0.77	0.61	-0.42	-0.13	0.91	-0.1	-0.98	0.49	-0.67		0.78	-0.78
Non Recurring	-0.57	0.92	0.93	-0.21	0.79	0.57	0.7	-0.28	-0.07	-0.81	0.61	-0.8	0.66	-0.29	-0.07	0.91	-0.07	-0.71	0.33	-0.48	0.78		-0.8
Selling And Marketing Expenses	0.56	-0.92	-0.93	0.29	-0.8	-0.7	-0.47	0.3	0.09	0.84	-0.37	0.84	-0.44	0.49	0.09	-0.91	0.09	0.69	-0.26	0.64	-0.78	-0.8

Click cells to compare fundamentals

Compass Therapeutics Account Relationship Matchups

Compass Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Net Interest Income	(485K)	(820K)	(341K)	2.4M	7.9M	8.3M
Interest Income	743K	88K	29K	2.4M	7.9M	8.3M
Depreciation And Amortization	2.9M	2.4M	1.6M	1.9M	1.9M	1.7M
Interest Expense	1.2M	908K	370K	2.4M	2.7M	2.8M
Selling General Administrative	11.6M	12.9M	10.9M	11.7M	12.2M	12.9M
Other Operating Expenses	34.1M	27.8M	31.3M	41.7M	50.4M	41.0M
Operating Income	(34.1M)	(27.8M)	(81.9M)	(41.7M)	(50.4M)	(52.9M)
Net Income From Continuing Ops	(34.7M)	(29.5M)	(82.2M)	(39.2M)	(42.5M)	(44.6M)
Ebit	(34.1M)	(27.7M)	(31.2M)	(39.3M)	(50.4M)	(52.9M)
Research Development	22.4M	14.9M	20.3M	30.0M	37.4M	27.9M
Ebitda	(31.2M)	(25.3M)	(29.6M)	(37.4M)	(48.5M)	(50.9M)
Total Operating Expenses	34.1M	27.8M	31.3M	41.7M	48.5M	40.6M
Reconciled Depreciation	2.1M	2.4M	1.6M	1.9M	1.9M	1.6M
Income Before Tax	(34.7M)	(29.5M)	(82.2M)	(39.2M)	(42.5M)	(44.6M)
Total Other Income Expense Net	(601K)	(1.7M)	(299K)	2.4M	7.9M	8.3M
Net Income Applicable To Common Shares	(34.7M)	(29.5M)	(82.2M)	(39.2M)	(35.3M)	(37.1M)
Net Income	(34.7M)	(29.5M)	(82.6M)	(36.8M)	(42.5M)	(44.6M)
Income Tax Expense	91K	32K	370K	(2.4M)	(2.2M)	(2.1M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Compass Historical Income Statement

About Compass Income Statement Analysis

Compass Therapeutics Income Statement Chart

Interest Income

Other Operating Expenses

Total Operating Expenses

Compass Therapeutics income statement Correlations

Compass Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Compass Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Compass Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Income	+ 1.0	Net Interest Income
Total Operating Expenses	+ 1.0	Other Operating Expenses
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Net Income	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Ebit
Net Income	+ 1.0	Income Before Tax

Non Operating Income Net Other	- 0.98	Income Tax Expense
Income Tax Expense	- 0.97	Interest Expense
Total Other Income Expense Net	- 0.94	Ebitda
Total Other Income Expense Net	- 0.94	Ebit
Selling And Marketing Expenses	- 0.93	Interest Income
Selling And Marketing Expenses	- 0.92	Net Interest Income